The stock price for Madison-based cancer screening and diagnostic test company Exact Sciences Corp. soared Wednesday after the company reported higher-than-expected sales in the first quarter.

Exact Sciences (Nasdaq: EXAS) on Tuesday reported total revenue of $602.5 million for the first quarter of 2023, a 24% increase compared with $486.6 million in the first quarter of 2022. This beat analysts’ revenue expectations by 11%, according to Zacks Consensus Estimate.

Click here to read the full article.